Dune Medical Devices appoints president, U.S., and CBO.

Dune Medical Devices, a developer of cancer detection products, has tapped William Densel as president of United States operations and chief business officer.

Based in New York, N.Y., and Israel, Dune Medical Devices develops and commercializes intra-operative devices for the detection of cancerous tissues. The company's first product, the MarginProbe, is focused on breast cancer surgery.

The MarginProbe comprises a sterile handheld probe and portable console. When the probe tip is applied to an excised lumpectomy segment, radio frequency signals are transmitted into the tissue and reflected back to the console where they are analyzed using a specialized algorithm to determine whether the tissue is cancerous.

"With our extensive U.S. pivotal trial under way, Dune is building its presence in North America. Bill's background, skill and dedication will be a major asset in our efforts to build our U.S. operations and global commercialization capabilities," said Dan Hashimshony, Dune Medical Devices CEO.

Densel most recently was vice president of marketing for the GYN Surgery Division of Bedford, Mass.-based Hologic Corp. He has more than 16 years of sales and marketing management experience in women's health and a range of other surgical specialties.

During his tenure at Hologic, he also managed the company's brain tumor radiation therapy business. Prior to Hologic, Densel held senior management roles at Natick, Mass.-based medical device maker Boston Scientific and Cambridge, Mass.-based Genzyme Biosurgery, which develops product lines for osteoarthritis relief, adhesion prevention, cartilage repair and severe burn treatment.